MMP9 is involved in glycation end-products induced increase of retinal vascular permeability in rats and the therapeutic effect of minocycline

Current Eye Research

Volumn 33, Issue 11-12, 2008, Pages 977-983

  Chen, Yong Dong ^a   Xu, Xun ^a   Xia, Xin ^a   Wu, Haixiang ^a   Liu, Kun ^a   Zheng, Zhi ^a   Zhu, Dongqing ^a  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

Author keywords

Advanced glycation end products; Blood retinal barrier; Diabetic retinopathy; Matrix metalloproteinase 9; Minocycline

Indexed keywords

ADVANCED GLYCATION END PRODUCT; BOVINE SERUM ALBUMIN; EVANS BLUE; GELATINASE B; MESSENGER RNA; MINOCYCLINE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLOOD RETINA BARRIER; BLOOD VESSEL PERMEABILITY; COMPARATIVE STUDY; CONTROLLED STUDY; IMMUNOHISTOCHEMISTRY; MALE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; RETINA BLOOD VESSEL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SPRAGUE DAWLEY RAT; WESTERN BLOTTING;

ANIMALS; CAPILLARY PERMEABILITY; DRUG COMBINATIONS; ENZYME INHIBITORS; GLYCOSYLATION END PRODUCTS, ADVANCED; MALE; MATRIX METALLOPROTEINASE 9; MICROCIRCULATION; MINOCYCLINE; RATS; RATS, SPRAGUE-DAWLEY; RETINA; RETINAL VESSELS; RNA, MESSENGER; SERUM ALBUMIN, BOVINE; UP-REGULATION;

EID: 57649121609     PISSN: 02713683     EISSN: 14602202     Source Type: Journal    
DOI: 10.1080/02713680802450984     Document Type: Article

References (32)

1. Frank RN. Diabetic retinopathy. N Engl J Med 2004;350:48-58.
2. Antonetti DA, Lieth E, Barber AJ, Gardner TW. Molecular mechanisms of vascular permeability in diabetic retinopathy. Semin Ophthalmol 1999;14:240-248.
3. Sander B, Larsen M, Moldow B, Lund-Andersen H. Diabetic macular edema: Passive and active transport of fluorescein through the blood-retina barrier. Invest Ophthalmol Vis Sci 2001;42:433-438.
4. Geiger B, Ayalon O. Cadherins. Annu Rev Cell Biol 1992;8:307-332.
5. Armulik A, Abramsson A, Betsholtz C. Endothelial/pericyte interactions. Circ Res 2005;97:512-523.
6. Stitt AW. Advanced glycation: An important pathological event in diabetic and age-related ocular disease. Br J Ophthalmol 2001;85:746-753.
7. Yamagishi S, Nakamura K, Matsui T. Advanced glycation end-products (AGEs) and their receptor (RAGE) system in diabetic retinopathy. Curr Drug Discov Technol 2006;3:83-88.
8. Chen BH, Jiang DY, Tang LS. [Advanced glycation end-products induce apoptosis and expression of apoptotic genes in cultured bovine retinal capillary pericytes]. Zhonghua Yan Ke Za Zhi 2003;39:224-227.
9. Xu X, Li Z, Luo D, et al. Exogenous advanced glycosylation end-products induce diabetes-like vascular dysfunction in normal rats: A factor in diabetic retinopathy. Graefes Arch Clin Exp Ophthalmol 2003;241:56-62.
10. Stitt AW, Bhaduri T, McMullen CB, Gardiner TA, Archer DB. Advanced glycation end-products induce blood-retinal barrier dysfunction in normoglycemic rats. Mol Cell Biol Res Commun 2000;3:380-388.
11. Cunningham LA, Wetzel M, Rosenberg GA. Multiple roles for MMPs and TIMPs in cerebral ischemia. Glia 2005;50:329-339.
12. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T. Regulation of matrix metalloproteinases: An overview. Mol Cell Biochem 2003;253:269-285.
13. Bergers G, Brekken R, McMahon G, et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat Cell Biol 2000;2:737-744.
14. Giebel SJ, Menicucci G, McGuire PG, Das A. Matrix metalloproteinases in early diabetic retinopathy and their role in alteration of the blood-retinal barrier. Lab Invest 2005;85:597-607.
15. Das A, McGuire PG, Eriqat C, et al. Human diabetic neovascular membranes contain high levels of urokinase and metalloproteinase enzymes. Invest Ophthalmol Vis Sci 1999;40:809-813.
16. Navaratna D, McGuire PG, Menicucci G, Das A. Proteolytic degradation of VE-cadherin alters the blood-retinal barrier in diabetes. Diabetes 2007;56:2380-2387.
17. Wang AL, Yu AC, Lau LT, et al. Minocycline inhibits LPS-induced retinal microglia activation. Neurochem Int 2005;47:152-158.
18. Krady JK, Basu A, Allen CM, et al. Minocycline reduces proinflammatory cytokine expression, microglial activation, and caspase-3 activation in a rodent model of diabetic retinopathy. Diabetes 2005;54:1559-1565.
19. Mathalone N, Lahat N, Rahat MA, Bahar-Shany K, Oron Y, Geyer O. The involvement of matrix metalloproteinases 2 and 9 in rat retinal ischemia. Graefes Arch Clin Exp Ophthalmol 2007;245:725-732.
20. Xu Q, Qaum T, Adamis AP. Sensitive blood-retinal barrier breakdown quantitation using Evans blue. Invest Ophthalmol Vis Sci 2001;42:789-794.
21. Hoffmann S, Friedrichs U, Eichler W, Rosenthal A, Wiedemann P. Advanced glycation end-products induce choroidal endothelial cell proliferation, matrix metalloproteinase-2, and VEGF upregulation in vitro. Graefes Arch Clin Exp Ophthalmol 2002;240:996-1002.
22. McLennan SV, Kelly DJ, Schache M, et al. Advanced glycation end-products decrease mesangial cell MMP-7: A role in matrix accumulation in diabetic nephropathy? Kidney Int 2007;72:481-488.
23. Yan SF, Ramasamy R, Naka Y, Schmidt AM. Glycation, inflammation, and RAGE: A scaffold for the macrovascular complications of diabetes and beyond. Circ Res 2003;93:1159-1169.
24. Kuniyasu H, Chihara Y, Kondo H. Differential effects between amphoterin and advanced glycation end-products on colon cancer cells. Int J Cancer 2003;104:722-727.
25. Yamagishi S, Yonekura H, Yamamoto Y, et al. Advanced glycation end-product-driven angiogenesis in vitro. Induction of the growth and tube formation of human microvascular endothelial cells through autocrine vascular endothelial growth factor. J Biol Chem 1997;272:8723-8730.
26. Lu M, Kuroki M, Amano S, et al. Advanced glycation end products increase retinal vascular endothelial growth factor expression. J Clin Invest 1998;101:1219-1224.
27. Hashimoto G, Inoki I, Fujii Y, Aoki T, Ikeda E, Okada Y. Matrix metalloproteinases cleave connective tissue growth factor and reactivate angiogenic activity of vascular endothelial growth factor 165. J Biol Chem 2002;277:36288-36295.
28. Yrjanheikki J, Tikka T, Keinanen R, Goldsteins G, Chan PH, Koistinaho J. A tetracycline derivative, minocycline, reduces inflammation and protects against focal cerebral ischemia with a wide therapeutic window. Proc Natl Acad Sci USA 1999;96:13496-13500.
29. Xu L, Fagan SC, Waller JL, et al. Low-dose intravenous minocycline is neuroprotective after middle cerebral artery occlusion-reperfusion in rats. BMC Neurol 2004;4:7.
30. Vincent JA, Mohr S. Inhibition of caspase-1/interleukin-1β signaling prevents degeneration of retinal capillaries in diabetes and galactosemia. Diabetes 2007;56:224-230.
31. Power C, Henry S, Del Bigio MR, et al. Intracerebral hemorrhage induces macrophage activation and matrix metalloproteinases. Ann Neurol 2003;53:731-742.
32. Fagan SC, Edwards DJ, Borlongan CV, et al. Optimal delivery of minocycline to the brain: Implication for human studies of acute neuroprotection. Exp Neurol 2004;186:248-251.